{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,14]],"date-time":"2026-10-14T18:23:23Z","timestamp":1792002203036,"version":"4.4.0"},"reference-count":49,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,1,1]],"date-time":"2025-01-01T00:00:00Z","timestamp":1735689600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,1,1]],"date-time":"2025-01-01T00:00:00Z","timestamp":1735689600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,1,28]],"date-time":"2025-01-28T00:00:00Z","timestamp":1738022400000},"content-version":"vor","delay-in-days":27,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100010585","name":"Basque Government Department of Health","doi-asserted-by":"publisher","award":["2016111056"],"award-info":[{"award-number":["2016111056"]}],"id":[{"id":"10.13039\/501100010585","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.es","elsevier.es","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Gaceta Sanitaria"],"published-print":{"date-parts":[[2025]]},"DOI":"10.1016\/j.gaceta.2025.102451","type":"journal-article","created":{"date-parts":[[2025,2,18]],"date-time":"2025-02-18T07:25:52Z","timestamp":1739863552000},"page":"102451","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":2,"special_numbering":"S1","title":["Cost-effectiveness of direct oral anticoagulants in non-valvular atrial fibrillation"],"prefix":"10.1016","volume":"39","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-5896-6148","authenticated-orcid":false,"given":"Inigo","family":"Gorostiza","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2202-0753","authenticated-orcid":false,"given":"Amaia","family":"Bilbao-Gonzalez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Javier","family":"Mar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.gaceta.2025.102451_bib0250","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1016\/j.recesp.2013.07.015","article-title":"Prevalence of atrial fibrillation in Spain. OFRECE study results","volume":"67","author":"G\u00f3mez-Doblas","year":"2014","journal-title":"Rev Esp Cardiol."},{"key":"10.1016\/j.gaceta.2025.102451_bib0255","doi-asserted-by":"crossref","first-page":"616","DOI":"10.1157\/13107118","article-title":"[Prevalence of atrial fibrillation in the Spanish population aged 60 years or more","volume":"60","author":"Cea-Calvo","year":"2007","journal-title":"The PREV-ICTUS study]. Rev Esp Cardiol."},{"key":"10.1016\/j.gaceta.2025.102451_bib0260","doi-asserted-by":"crossref","first-page":"2370","DOI":"10.1001\/jama.285.18.2370","article-title":"Prevalence of diagnosed atrial fibrillation in adults: national implications for rhythm management and stroke prevention: the AnTicoagulation and Risk Factors in Atrial Fibrillation (ATRIA) Study","volume":"285","author":"Go","year":"2001","journal-title":"JAMA."},{"key":"10.1016\/j.gaceta.2025.102451_bib0265","doi-asserted-by":"crossref","first-page":"2298","DOI":"10.1161\/CIRCULATIONAHA.111.055079","article-title":"Net clinical benefit of warfarin in patients with atrial fibrillation: a report from the Swedish atrial fibrillation cohort study","volume":"125","author":"Friberg","year":"2012","journal-title":"Circulation."},{"key":"10.1016\/j.gaceta.2025.102451_bib0270","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1093\/eurheartj\/ehaa612","volume":"42","author":"Hindricks","year":"2021","journal-title":"Eur Heart J."},{"key":"10.1016\/j.gaceta.2025.102451_bib0275","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1378\/chest.09-1584","article-title":"Refining clinical risk stratification for predicting stroke and thromboembolism in atrial fibrillation using a novel risk factor-based approach: the Euro Heart Survey on atrial fibrillation","volume":"137","author":"Lip","year":"2010","journal-title":"Chest."},{"issue":"3 Suppl","key":"10.1016\/j.gaceta.2025.102451_bib0280","doi-asserted-by":"crossref","first-page":"204S","DOI":"10.1378\/chest.126.3_suppl.204S","article-title":"The pharmacology and management of the vitamin K antagonists: the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy","volume":"126","author":"Ansell","year":"2004","journal-title":"Chest."},{"key":"10.1016\/j.gaceta.2025.102451_bib0285","first-page":"680","article-title":"Cost-effectiveness analysis comparing apixaban and acenocoumarol in the prevention of stroke in patients with nonvalvular atrial fibrillation in Spain","volume":"68","author":"Bar\u00f3n-Esquivias","year":"2015","journal-title":"Rev Esp Cardiol."},{"key":"10.1016\/j.gaceta.2025.102451_bib0290","doi-asserted-by":"crossref","first-page":"367","DOI":"10.1007\/s40273-014-0136-z","article-title":"gains in applied studies: a review of cost-utility analyses published in 2010","volume":"32","author":"Wisl\u00f8ff","year":"2014","journal-title":"Pharmacoeconomics."},{"key":"10.1016\/j.gaceta.2025.102451_bib0295","doi-asserted-by":"crossref","first-page":"601","DOI":"10.1007\/s40273-014-0152-z","article-title":"Economic evaluation of warfarin, dabigatran, rivaroxaban, and apixaban for stroke prevention in atrial fibrillation","volume":"32","author":"Wisl\u00f8ff","year":"2014","journal-title":"Pharmacoeconomics."},{"key":"10.1016\/j.gaceta.2025.102451_bib0300","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1136\/bmjebm-2020-111634","article-title":"Economic evaluation of direct oral anticoagulants (DOACs) versus vitamin K antagonists (VKAs) for stroke prevention in patients with atrial fibrillation: a systematic review and meta-analysis","volume":"27","author":"Noviyani","year":"2022","journal-title":"BMJ Evid Based Med."},{"key":"10.1016\/j.gaceta.2025.102451_bib0305","doi-asserted-by":"crossref","first-page":"e0266658","DOI":"10.1371\/journal.pone.0266658","article-title":"Real-world cost-effectiveness analysis of NOACs versus VKA for stroke prevention in Spain","volume":"17","author":"Escobar-Cervantes","year":"2022","journal-title":"PLoS One."},{"key":"10.1016\/j.gaceta.2025.102451_bib0310","doi-asserted-by":"crossref","first-page":"20","DOI":"10.7326\/M21-0717","article-title":"Risk for recurrent venous thromboembolism and bleeding with apixaban compared with rivaroxaban: an analysis of real-world data","volume":"175","author":"Dawwas","year":"2022","journal-title":"Ann Intern Med."},{"key":"10.1016\/j.gaceta.2025.102451_bib0315","doi-asserted-by":"crossref","first-page":"766","DOI":"10.1097\/EDE.0b013e3181875e61","article-title":"Observational studies analyzed like randomized experiments: an application to postmenopausal hormone therapy and coronary heart disease","volume":"19","author":"Hern\u00e1n","year":"2008","journal-title":"Epidemiology."},{"key":"10.1016\/j.gaceta.2025.102451_bib0320","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1186\/2191-1991-3-21","article-title":"Do health economic evaluations using observational data provide reliable assessment of treatment effects?","volume":"3","author":"Rovithis","year":"2013","journal-title":"Health Econ Rev."},{"key":"10.1016\/j.gaceta.2025.102451_bib0325","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1016\/j.gaceta.2021.02.006","article-title":"Stratified cost-utility analysis of total hip arthroplasty in displaced femoral neck fracture","volume":"36","author":"Larra\u00f1aga","year":"2022","journal-title":"Gac Sanit."},{"key":"10.1016\/j.gaceta.2025.102451_bib0330","doi-asserted-by":"crossref","first-page":"352","DOI":"10.1016\/j.gaceta.2016.05.002","article-title":"Cost-utility analysis of an integrated care model for multimorbid patients based on a clinical trial","volume":"30","author":"Lanzeta","year":"2016","journal-title":"Gac Sanit."},{"key":"10.1016\/j.gaceta.2025.102451_bib0335","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1159\/000521288","article-title":"Charlson Comorbidity Index: a critical review of clinimetric properties","volume":"91","author":"Charlson","year":"2022","journal-title":"Psychother Psychosom."},{"key":"10.1016\/j.gaceta.2025.102451_bib0340","doi-asserted-by":"crossref","first-page":"188","DOI":"10.1097\/MLR.0000000000000471","article-title":"The best use of the Charlson Comorbidity Index with electronic health care database to predict mortality","volume":"54","author":"Bannay","year":"2016","journal-title":"Med Care."},{"key":"10.1016\/j.gaceta.2025.102451_bib0345","doi-asserted-by":"crossref","first-page":"1093","DOI":"10.1378\/chest.10-0134","article-title":"A novel user-friendly score (HAS-BLED) to assess 1-year risk of major bleeding in patients with atrial fibrillation: the Euro Heart Survey","volume":"138","author":"Pisters","year":"2010","journal-title":"Chest."},{"key":"10.1016\/j.gaceta.2025.102451_bib0350","series-title":"Methods for the economic evaluation of health care programmes","author":"Drummond","year":"2005"},{"key":"10.1016\/j.gaceta.2025.102451_bib0355","doi-asserted-by":"crossref","first-page":"785","DOI":"10.1007\/s40273-020-00914-6","article-title":"Calculating and interpreting ICERs and net benefit","volume":"38","author":"Paulden","year":"2020","journal-title":"Pharmacoeconomics."},{"key":"10.1016\/j.gaceta.2025.102451_bib0360","doi-asserted-by":"crossref","first-page":"746","DOI":"10.1002\/hec.3633","article-title":"Estimating a cost-effectiveness threshold for the Spanish NHS","volume":"27","author":"Vallejo-Torres","year":"2018","journal-title":"Health Econ."},{"key":"10.1016\/j.gaceta.2025.102451_bib0365","series-title":"Decision modelling for health economic evaluation","author":"Briggs","year":"2006"},{"key":"10.1016\/j.gaceta.2025.102451_bib0370","series-title":"Statistical analysis of cost-effectiveness data","author":"Willan","year":"2006"},{"key":"10.1016\/j.gaceta.2025.102451_bib0375","doi-asserted-by":"crossref","first-page":"2337","DOI":"10.1007\/s11136-018-1877-5","article-title":"Validity of the EQ-5D-5L and reference norms for the Spanish population","volume":"27","author":"Hernandez","year":"2018","journal-title":"Qual Life Res."},{"key":"10.1016\/j.gaceta.2025.102451_bib0380","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1080\/16078454.2021.1892329","article-title":"Quality of life in patients with nonvalvular atrial fibrillation treated with oral anticoagulants","volume":"26","author":"Gabilondo","year":"2021","journal-title":"Hematology."},{"key":"10.1016\/j.gaceta.2025.102451_bib0385","doi-asserted-by":"crossref","first-page":"800","DOI":"10.1177\/0272989X11401031","article-title":"Catalogue of EQ-5D scores for the United Kingdom","volume":"31","author":"Sullivan","year":"2011","journal-title":"Med Decis Making."},{"key":"10.1016\/j.gaceta.2025.102451_bib0390","doi-asserted-by":"crossref","first-page":"326","DOI":"10.1111\/j.1524-4733.2007.00186.x","article-title":"Using real-world data for coverage and payment decisions: the ISPOR Real-World Data Task Force report","volume":"10","author":"Garrison","year":"2007","journal-title":"Value Health."},{"key":"10.1016\/j.gaceta.2025.102451_bib0395","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1080\/00273171.2011.568786","article-title":"An introduction to propensity score methods for reducing the effects of confounding in observational studies","volume":"46","author":"Austin","year":"2011","journal-title":"Multivariate Behav Res."},{"key":"10.1016\/j.gaceta.2025.102451_bib0400","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1093\/pan\/mpr025","article-title":"Entropy balancing for causal effects: a multivariate reweighting method to produce balanced samples in observational studies","volume":"20","author":"Hainmueller","year":"2012","journal-title":"Political Analysis."},{"key":"10.1016\/j.gaceta.2025.102451_bib0405","doi-asserted-by":"crossref","first-page":"3388","DOI":"10.1002\/sim.5753","article-title":"A tutorial on propensity score estimation for multiple treatments using generalized boosted models","volume":"32","author":"McCaffrey","year":"2013","journal-title":"Stat Med."},{"key":"10.1016\/j.gaceta.2025.102451_bib0410","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1016\/j.jval.2015.02.001","article-title":"Cost-effectiveness analysis alongside clinical trials II-An ISPOR Good Research Practices Task Force report","volume":"18","author":"Ramsey","year":"2015","journal-title":"Value Health."},{"key":"10.1016\/j.gaceta.2025.102451_bib0415","series-title":"Economic evaluation in clinical trials","author":"Glick","year":"2014"},{"key":"10.1016\/j.gaceta.2025.102451_bib0420","first-page":"247","article-title":"[Comparison of the cost-utility of direct oral anticoagulants for the prevention of stroke in patients with atrial fibrillation in Spain]","volume":"6","author":"Monreal-Bosch","year":"2017","journal-title":"Rev Neurol."},{"key":"10.1016\/j.gaceta.2025.102451_bib0425","doi-asserted-by":"crossref","first-page":"901","DOI":"10.1016\/j.recesp.2012.06.006","article-title":"Cost-effectiveness of dabigatran for stroke prevention in non-valvular atrial fibrillation in Spain","volume":"65","author":"Gonz\u00e1lez-Juanatey","year":"2012","journal-title":"Rev Esp Cardiol."},{"key":"10.1016\/j.gaceta.2025.102451_bib0430","doi-asserted-by":"crossref","first-page":"19","DOI":"10.36469\/9823","article-title":"Cost-effectiveness analysis of rivaroxaban versus acenocoumarol in the prevention of stroke in patients with non-valvular atrial fibrillation in Spain","volume":"4","author":"Rubio-Terr\u00e9s","year":"2016","journal-title":"J Health Econ Outcomes Res."},{"key":"10.1016\/j.gaceta.2025.102451_bib0435","doi-asserted-by":"crossref","first-page":"398","DOI":"10.1016\/j.recesp.2018.03.017","article-title":"Would the use of edoxaban be cost-effective for the prevention of stroke and systemic embolism in patients with nonvalvular atrial fibrillation in Spain?","volume":"72","author":"Lekuona","year":"2019","journal-title":"Rev Esp Cardiol."},{"key":"10.1016\/j.gaceta.2025.102451_bib0440","doi-asserted-by":"crossref","first-page":"e22054","DOI":"10.1097\/MD.0000000000022054","article-title":"Cost-effectiveness of direct oral anticoagulants versus vitamin K antagonist in atrial fibrillation: a study protocol using real-world data from Catalonia (FantasTIC Study)","volume":"99","author":"Hern\u00e1ndez-Rojas","year":"2020","journal-title":"Medicine."},{"key":"10.1016\/j.gaceta.2025.102451_bib0445","doi-asserted-by":"crossref","first-page":"845","DOI":"10.1016\/j.amjcard.2012.05.011","article-title":"Cost-effectiveness of rivaroxaban compared to warfarin for stroke prevention in atrial fibrillation","volume":"110","author":"Lee","year":"2012","journal-title":"Am J Cardiol."},{"key":"10.1016\/j.gaceta.2025.102451_bib0450","doi-asserted-by":"crossref","first-page":"1","DOI":"10.7326\/0003-4819-154-1-201101040-00289","article-title":"Cost-effectiveness of dabigatran compared with warfarin for stroke prevention in atrial fibrillation","volume":"154","author":"Freeman","year":"2011","journal-title":"Ann Intern Med."},{"key":"10.1016\/j.gaceta.2025.102451_bib0455","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1007\/s10198-019-01123-5","article-title":"The contribution of real-world evidence to cost-effectiveness analysis: case study of Dabigatran etexilate in France","volume":"21","author":"de Pouvourville","year":"2020","journal-title":"Eur J Health Econ."},{"key":"10.1016\/j.gaceta.2025.102451_bib0460","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1007\/s40261-021-01002-z","article-title":"Cost-effectiveness of direct non-vitamin K oral anticoagulants versus vitamin K antagonists for the management of patients with non-valvular atrial fibrillation based on available \u00abReal-World\u00bb evidence: the Italian National Health System perspective","volume":"41","author":"Lorenzoni","year":"2021","journal-title":"Clin Drug Investig."},{"key":"10.1016\/j.gaceta.2025.102451_bib0465","doi-asserted-by":"crossref","first-page":"e0225301","DOI":"10.1371\/journal.pone.0225301","article-title":"Real-world cost-effectiveness of rivaroxaban compared with vitamin K antagonists in the context of stroke prevention in atrial fibrillation in France","volume":"15","author":"Bowrin","year":"2020","journal-title":"PLoS One."},{"key":"10.1016\/j.gaceta.2025.102451_bib0470","doi-asserted-by":"crossref","first-page":"192","DOI":"10.1016\/j.clinthera.2013.12.011","article-title":"Cost-effectiveness of apixaban versus other new oral anticoagulants for stroke prevention in atrial fibrillation","volume":"36","author":"Lip","year":"2014","journal-title":"Clin Ther."},{"key":"10.1016\/j.gaceta.2025.102451_bib0475","doi-asserted-by":"crossref","first-page":"1846","DOI":"10.1177\/0962280219878215","article-title":"An omnibus approach to assess covariate balance in observational studies using the distance covariance","volume":"29","author":"Andrei","year":"2020","journal-title":"Stat Methods Med Res."},{"key":"10.1016\/j.gaceta.2025.102451_bib0480","doi-asserted-by":"crossref","first-page":"805","DOI":"10.1002\/hec.987","article-title":"A propensity score approach to estimating the cost-effectiveness of medical therapies from observational data","volume":"14","author":"Mitra","year":"2005","journal-title":"Health Econ."},{"key":"10.1016\/j.gaceta.2025.102451_bib0485","doi-asserted-by":"crossref","first-page":"979","DOI":"10.1002\/pds.4570","article-title":"Methodological challenges in assessment of current use of warfarin among patients with atrial fibrillation using dispensation data from administrative health care databases","volume":"27","author":"Sinyavskaya","year":"2018","journal-title":"Pharmacoepidemiol Drug Saf."},{"key":"10.1016\/j.gaceta.2025.102451_bib0490","doi-asserted-by":"crossref","first-page":"901","DOI":"10.1186\/s12913-019-4711-z","article-title":"Modeling patients\u2019 time, travel, and monitoring costs in anticoagulation management: societal savings achievable with the shift from warfarin to direct oral anticoagulants","volume":"19","author":"Leminen","year":"2019","journal-title":"BMC Health Serv Res."}],"container-title":["Gaceta Sanitaria"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0213911125000056?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0213911125000056?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,4]],"date-time":"2025-11-04T14:04:32Z","timestamp":1762265072000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0213911125000056"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025]]},"references-count":49,"alternative-id":["S0213911125000056"],"URL":"https:\/\/doi.org\/10.1016\/j.gaceta.2025.102451","relation":{},"ISSN":["0213-9111"],"issn-type":[{"value":"0213-9111","type":"print"}],"subject":[],"published":{"date-parts":[[2025]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Cost-effectiveness of direct oral anticoagulants in non-valvular atrial fibrillation","name":"articletitle","label":"Article Title"},{"value":"Gaceta Sanitaria","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.gaceta.2025.102451","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 SESPAS. Published by Elsevier Espa\u00f1a, S.L.U.","name":"copyright","label":"Copyright"}],"article-number":"102451"}}